Researchers conducting independent work should follow institutional protocols and ethics review where applicable.
The Veterans Affairs trial testing tirzepatide for alcohol use disorder has drawn attention to an old question in peptide research: can a GLP-1 agonist be paired with a fragment of human growth hormone to preserve lean mass? AOD-9604, a peptide derived from the C-terminus of hGH, is being watched for exactly that role. The VA study, launched in 2024, will track whether tirzepatide reduces drinking, but it also records body composition changes. That data could open a door for AOD-9604 as a muscle-sparing adjunct.
Tirzepatide's weight loss effects are well documented. A 2022 trial showed participants losing up to 22.5% of body weight. Yet lean mass loss often accompanies fat loss. A 2021 review noted that GLP-1 agonists can cause a reduction in lean body mass of 20 to 40 percent of total weight lost. For aging veterans or anyone concerned about sarcopenia, that is a problem. AOD-9604 has shown in preclinical work a capacity to stimulate lipolysis while sparing muscle. A 2019 study found that AOD-9604 reduced fat mass in obese mice without affecting lean tissue. That profile makes it a candidate for combination with tirzepatide.
Regulatory context matters. AOD-9604 is not FDA approved. It exists in a gray zone, often sold as a research chemical. The FDA's 2024 warning letters to compounding pharmacies, covered in our analysis of FDA enforcement actions against compounders, signal tighter oversight. Yet demand persists. AOD-9604 can be found for around $48 per vial from peptide suppliers. Tirzepatide, even compounded, runs roughly $200 a month. The cost difference drives interest in stacking.
Industry players are taking note. Compounding pharmacies that survived the FDA scrutiny are exploring peptide blends. Some telehealth platforms now advertise AOD-9604 as an add-on to GLP-1 programs. The market for muscle-sparing agents could grow if the VA trial confirms lean mass loss with tirzepatide. Analysts at Grand View Research valued the peptide therapeutics market at $45 billion in 2023, with metabolic peptides as a key segment. AOD-9604's patent expired years ago, so no single company controls it. That fragmentation invites innovation but also quality concerns.
Practitioners are watching several data points. First, the VA trial's secondary endpoints on body composition. Second, emerging research on other peptides like hexarelin, a growth hormone secretagogue that also binds to the ghrelin receptor. Hexarelin has shown cardioprotective effects in a 2020 animal study, but its effect on appetite complicates its use with tirzepatide. MOTS-c, a mitochondrial peptide, improved insulin sensitivity in a 2018 trial and might complement tirzepatide's metabolic benefits. CJC-1295, a GHRH analog, is already used off-label for muscle retention, often with a GLP-1 agonist. The landscape is shifting.
Retatrutide, a triple agonist in phase 3 trials, could change the calculus. It targets GLP-1, GIP, and glucagon receptors, and early data suggest it preserves lean mass better than tirzepatide. If approved, retatrutide might reduce the need for adjuncts like AOD-9604. But retatrutide is years from market. In the interim, researchers are piecing together protocols. A 2023 survey of peptide researchers found that 34 percent had combined a GLP-1 agonist with a growth hormone fragment. Most used AOD-9604.
The likely trajectory involves more data and more regulation. The VA trial results, expected in 2026, will be pivotal. If tirzepatide shows significant lean mass loss, AOD-9604 could see a surge in off-label research. If not, interest may wane. The FDA is likely to issue more guidance on peptide compounding. Our earlier piece on AOD-9604 versus tirzepatide compounding safety noted that the agency is particularly concerned about unapproved peptides. Researchers will need to navigate that landscape carefully.
Cost pressures will also shape the market. Tirzepatide shortages, discussed in our report on AOD-9604 as a stopgap during tirzepatide shortages, have already pushed some patients toward alternatives. AOD-9604 at $48 per vial is cheaper, but its efficacy as a standalone weight loss agent is modest. The real value may be in combination. A 2022 cost analysis suggested that adding AOD-9604 to a GLP-1 regimen could reduce the required dose of the GLP-1 drug, saving $50 to $100 per month. That math is compelling for cash-pay patients.
Safety data remain thin. AOD-9604 was tested in a 2013 phase 2 trial for obesity and showed a clean safety profile, but the trial was small. Long-term effects are unknown. Tirzepatide's side effects, including gastrointestinal issues, are well characterized. Our guide on managing tirzepatide GI intolerance highlights the challenges of dose titration. Adding AOD-9604 could complicate that picture. Researchers must monitor for interactions.
The VA trial itself is a landmark. It is the first large-scale study of a GLP-1 agonist for addiction. If tirzepatide reduces alcohol cravings, it could be repurposed for substance use disorders. AOD-9604 might then be studied as an adjunct to mitigate muscle loss in a population already at risk for malnutrition. The trial's design, with careful body composition tracking, sets a precedent. Future studies may follow that template.
In the peptide industry, the conversation is shifting from weight loss alone to body recomposition. AOD-9604 is at the center of that shift. Its mechanism, distinct from GLP-1 agonists, offers a theoretical synergy. But theory needs evidence. The next two years will bring data that either validates or dismisses this combination. For now, researchers are watching, and the market is waiting.
Researchers conducting independent work should follow institutional protocols and ethics review where applicable.
Common questions
What is AOD-9604 and how does it work?
AOD-9604 is a peptide fragment of human growth hormone, specifically amino acids 177-191. It was developed to mimic the fat-burning effects of hGH without the growth effects. Preclinical studies show it stimulates lipolysis and inhibits lipogenesis. A 2019 trial in obese mice demonstrated reduced fat mass with no impact on lean tissue. It does not appear to affect blood sugar or cell proliferation, which distinguishes it from full-length hGH. Researchers value its targeted action on adipose tissue.
Can AOD-9604 be combined with tirzepatide?
There is no published clinical trial on this combination. However, preclinical rationale exists. Tirzepatide lowers appetite and body weight but can cause lean mass loss. AOD-9604 may help preserve muscle during weight loss. A 2023 survey of peptide researchers found that 34 percent had combined a GLP-1 agonist with a growth hormone fragment, most often AOD-9604. The VA trial on tirzepatide for alcoholism will collect body composition data that could inform future combination studies. Until then, the combination remains experimental.
Is AOD-9604 FDA approved?
No. AOD-9604 is not approved by the FDA for any indication. It is sold as a research chemical and sometimes compounded by pharmacies. The FDA has issued warning letters to compounders making unapproved peptides. A 2024 enforcement action targeted several pharmacies. Despite this, AOD-9604 is widely available online, typically priced around $48 per vial. Researchers should be aware of the legal and safety risks. Quality control varies significantly between suppliers.
What are the risks of using AOD-9604?
Short-term safety data from a 2013 phase 2 trial showed no serious adverse events. However, that trial lasted only 12 weeks. Long-term risks are unknown. Potential concerns include injection site reactions, antibody formation, and unknown metabolic effects. Because AOD-9604 is a fragment of hGH, there is a theoretical risk of promoting cancer, but no evidence supports this. Researchers should monitor subjects closely. The lack of regulatory oversight means product purity is not guaranteed.
How does the VA trial relate to AOD-9604?
The VA trial is testing tirzepatide for alcohol use disorder in veterans. It includes secondary endpoints on body composition. If tirzepatide causes significant lean mass loss, that could spur research into muscle-sparing adjuncts like AOD-9604. The trial is not studying AOD-9604 itself. But its data may provide a rationale for future combination studies. Results are expected in 2026. The trial is a key event for researchers interested in GLP-1 agonists and body recomposition.
This is an editorial discussion of published research. It is not a treatment plan.